PCN70 Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With Kras Wild-Type Tumours in the United Kingdom
Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1171
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2011
Authors
Publisher
Elsevier BV